Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

被引:9
作者
Chava, Suresh [1 ]
Bugide, Suresh [1 ]
Gupta, Romi [1 ]
Wajapeyee, Narendra [1 ]
机构
[1] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2020年 / 156期
基金
美国国家卫生研究院;
关键词
Medicine; Issue; 156; NK cells; cancer; migration; cytotoxicity; transcription factors; flow cytometry; IMMUNE-SYSTEM; TARGET-CELLS; IN-VITRO; INNATE;
D O I
10.3791/60714
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Natural killer (NK) cells are a subset of the cytotoxic lymphocyte population of the innate immune system and participate as a first line of defense by clearing pathogen-infected, malignant, and stressed cells. The ability of NK cells to eradicate cancer cells makes them an important tool in the fight against cancer. Several new immune-based therapies are under investigation for cancer treatment which rely either on enhancing NK cell activity or increasing the sensitivity of cancer cells to NK cell-mediated eradication. However, to effectively develop these therapeutic approaches, cost-effective in vitro assays to monitor NK cell-mediated cytotoxicity and migration are also needed. Here, we present two in vitro protocols that can reliably and reproducibly monitor the effect of NK-cell cytotoxicity on cancer cells (or other target cells). These protocols are non-radioactivity-based, simple to set up, and can be scaled up for high-throughput screening. We also present a flow cytometry-based protocol to quantitatively monitor NK cell migration, which can also be scaled up for high-throughput screening. Collectively, these three protocols can be used to monitor key aspects of NK cell activity that are necessary for the cells' ability to eradicate dysfunctional target cells.
引用
收藏
页数:7
相关论文
共 30 条
  • [1] Natural Killer Cells: Development, Maturation, and Clinical Utilization
    Abel, Alex M.
    Yang, Chao
    Thakar, Monica S.
    Malarkannan, Subramaniam
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] CD107a as a functional marker for the identification of natural killer cell activity
    Alter, G
    Malenfant, JM
    Altfeld, M
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 294 (1-2) : 15 - 22
  • [4] Immunotherapy of cancer
    Borghaei, Hossein
    Smith, Mitchell R.
    Campbell, Kerry S.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) : 41 - 54
  • [5] BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
  • [6] A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes
    Bryceson, Yenan T.
    Pende, Daniela
    Maul-Pavicic, Andrea
    Gilmour, Kimberly C.
    Ufheil, Heike
    Vraetz, Thomas
    Chiang, Samuel C.
    Marcenaro, Stefania
    Meazza, Raffaella
    Bondzio, Ilka
    Walshe, Denise
    Janka, Gritta
    Lehmberg, Kai
    Beutel, Karin
    zur Stadt, Udo
    Binder, Nadine
    Arico, Maurizio
    Moretta, Lorenzo
    Henter, Jan-Inge
    Ehl, Stephan
    [J]. BLOOD, 2012, 119 (12) : 2754 - 2763
  • [7] Expression Analysis of the Ligands for the Natural Killer Cell Receptors NKp30 and NKp44
    Byrd, Andreina
    Hoffmann, Sabrina C.
    Jarahian, Mostafa
    Momburg, Frank
    Watzl, Carsten
    [J]. PLOS ONE, 2007, 2 (12):
  • [8] Natural killer cells and other innate lymphoid cells in cancer
    Chiossone, Laura
    Dumas, Pierre-Yves
    Vienne, Margaux
    Vivier, Eric
    [J]. NATURE REVIEWS IMMUNOLOGY, 2018, 18 (11) : 671 - 688
  • [9] The evolution of adaptive immune systems
    Cooper, MD
    Alder, MN
    [J]. CELL, 2006, 124 (04) : 815 - 822
  • [10] Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
    Fehniger, TA
    Bluman, EM
    Porter, MM
    Mrózek, E
    Cooper, MA
    VanDeusen, JB
    Frankel, SR
    Stock, W
    Caligiuri, MA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (01) : 117 - 124